Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Nexalin Technology, Inc. (NXL : NSDQ)
 
 • Company Description   
Nexalin Technology Inc. designs and develops neurostimulation products for mental health epidemic. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. Nexalin Technology Inc. is based in Houston, Texas.

Number of Employees: 6

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.27 Daily Weekly Monthly
20 Day Moving Average: 128,164 shares
Shares Outstanding: 13.33 (millions)
Market Capitalization: $16.93 (millions)
Beta: 4.67
52 Week High: $4.49
52 Week Low: $0.53
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -31.35% -34.95%
12 Week -61.63% -58.55%
Year To Date -53.99% -52.18%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1776 YORKTOWN SUITE 550
-
Houston,TX 77056
USA
ph: 832-260-0222
fax: -
nxl@crescendo-ir.com http://www.nexalin.com
 
 • General Corporate Information   
Officers
Mark White - Chief Executive Officer and Chief Financial Office
Carolyn Shelton - Senior Vice President of Quality; Clinical and Reg
Alan Kazden - Director
Ben Hu - Director
Leslie Bernhard - Director

Peer Information
Nexalin Technology, Inc. (EVOL)
Nexalin Technology, Inc. (RAMP)
Nexalin Technology, Inc. (LGTY)
Nexalin Technology, Inc. (ALOT)
Nexalin Technology, Inc. (CXT)
Nexalin Technology, Inc. (TGHI)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Technology Services
Sector: Business Services
CUSIP: 65345B201
SIC: 3845
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/24
Next Expected EPS Date: 05/09/25
Share - Related Items
Shares Outstanding: 13.33
Most Recent Split Date: (:1)
Beta: 4.67
Market Capitalization: $16.93 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/09/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.60
Price/Cash Flow: -
Price / Sales: 100.16
EPS Growth
vs. Year Ago Period: -180.00%
vs. Previous Quarter: -21.74%
Sales Growth
vs. Year Ago Period: 28.57%
vs. Previous Quarter: -25.00%
ROE
03/31/25 - -
12/31/24 - -247.11
09/30/24 - -187.59
ROA
03/31/25 - -
12/31/24 - -219.24
09/30/24 - -167.21
Current Ratio
03/31/25 - -
12/31/24 - 7.24
09/30/24 - 16.42
Quick Ratio
03/31/25 - -
12/31/24 - 6.92
09/30/24 - 15.89
Operating Margin
03/31/25 - -
12/31/24 - -4,500.59
09/30/24 - -3,407.36
Net Margin
03/31/25 - -
12/31/24 - -4,501.18
09/30/24 - -3,407.98
Pre-Tax Margin
03/31/25 - -
12/31/24 - -4,511.59
09/30/24 - -3,418.41
Book Value
03/31/25 - -
12/31/24 - 0.28
09/30/24 - 0.47
Inventory Turnover
03/31/25 - -
12/31/24 - 0.23
09/30/24 - 0.22
Debt-to-Equity
03/31/25 - -
12/31/24 - 0.00
09/30/24 - 0.00
Debt-to-Capital
03/31/25 - -
12/31/24 - 0.00
09/30/24 - 0.00
 

Powered by Zacks Investment Research ©